Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

Neuronetics (NASDAQ: STIM) will release its fourth quarter 2025 financial and operating results before market open on Tuesday, March 17, 2026.

The company will host a live conference call at 8:30 a.m. Eastern Time the same day, available via webcast in listen-only mode; telephone registration is optional but recommended 10 minutes early.

News Market Reaction – STIM

-1.55%

4 alerts

-1.55% News Effect

+18.8% Peak Tracked

-$1M Valuation Impact

$95M Market Cap

0.1x Rel. Volume

On the day this news was published, STIM declined 1.55%, reflecting a mild negative market reaction. Argus tracked a peak move of +18.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $95M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings release date: March 17, 2026 Conference call time: 8:30 a.m. ET Quarter reported: Fourth quarter 2025

3 metrics

Earnings release date March 17, 2026 Planned release date for Q4 2025 financial and operating results

Conference call time 8:30 a.m. ET Scheduled time for Q4 2025 results conference call

Quarter reported Fourth quarter 2025 Period covered by upcoming financial and operating results

Market Reality Check

Price: $1.33 Vol: Volume 754,259 is 0.25x t...

low vol

$1.33 Last Close

Volume Volume 754,259 is 0.25x the 20-day average of 2,987,303, indicating relatively muted trading ahead of the earnings date. low

Technical Shares at $1.29 are trading below the 200-day MA of $2.76 and sit 78.21% under the 52-week high, only 7.32% above the 52-week low.

Peers on Argus

STIM fell 3.73% while the only peer in the momentum scanner, CERS, declined 7.50...

1 Down

STIM fell 3.73% while the only peer in the momentum scanner, CERS, declined 7.509999722242355% without news. Several sector peers (BSGM, CVRX, ELMD, TLSI, BWAY) showed modest gains, suggesting STIM’s move was more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Prelim Q4/FY results	Positive	+23.3%	Preliminary Q4 and FY2025 revenue, cash flow, and system shipment update.
Nov 20	Conference participation	Neutral	-12.8%	Announcement of management fireside chat at a healthcare investor conference.
Nov 12	Coverage expansion	Positive	-1.8%	TRICARE West policy change expanding NeuroStar TMS coverage for adolescents.
Nov 04	Q3 earnings, guidance	Positive	+3.6%	Q3 2025 results, Greenbrook-driven growth, updated full-year and Q4 guidance.
Oct 31	Inducement grants	Neutral	+4.5%	Inducement RSU awards to new employees under Nasdaq inducement rules.

Pattern Detected

Recent fundamental updates, especially earnings and preliminary results, have often been followed by positive price moves, while a major reimbursement win in November saw a slight negative reaction, indicating some disconnect between news quality and immediate trading.

Recent Company History

Over the last few months, Neuronetics has reported multiple milestones. On Oct 31, 2025, it detailed inducement RSU grants. Q3 2025 results on Nov 4 showed strong revenue growth and updated guidance, with a modest positive reaction. A TRICARE coverage expansion on Nov 12 and a conference participation notice on Nov 20 saw muted-to-negative responses. Preliminary Q4 and FY2025 results on Feb 10, 2026 drove a strong positive move. Today’s earnings-date notice follows that strong preliminary update.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-03

The company has an active Form S-3 shelf registration filed on 2025-07-03, currently shown as not yet effective, with at least one usage via a 424B5 supplement on 2025-08-06. This structure can facilitate future registered offerings when effective.

Market Pulse Summary

This announcement sets the timetable for Neuronetics’ Q4 2025 results, with the release on March 17,...

Analysis

This announcement sets the timetable for Neuronetics’ Q4 2025 results, with the release on March 17, 2026 and a conference call at 8:30 a.m. ET. It follows strong preliminary Q4 and FY2025 metrics reported in February and comes as the stock trades near its 52-week low. Investors may watch how final numbers compare with prior guidance and how management frames growth, cash flow, and capital structure plans.

Key Terms

nasdaq

1 terms

nasdaq financial

"Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”)"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

AI-generated analysis. Not financial advice.

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/t8xxgfnr. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy (“NeuroStar Therapy”) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System (the “NeuroStar System”) and associated treatment sessions to customers, Neuronetics operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy, SPRAVATO, and other treatment modalities for the treatment of MDD and other mental health disorders.

NeuroStar Therapy is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also cleared by the U.S. Food and Drug Administration as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15 to 21 with MDD. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results.

Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

FAQ

When will Neuronetics (STIM) report fourth quarter 2025 results?

Neuronetics will release fourth quarter 2025 financial and operating results before market open on March 17, 2026. According to Neuronetics, the report precedes a conference call the same day where management will review results and take no live questions in webcast listen-only mode.

What time is the Neuronetics (STIM) conference call on March 17, 2026?

The conference call is scheduled for 8:30 a.m. Eastern Time on March 17, 2026. According to Neuronetics, the call will be broadcast live in listen-only mode via webcast and telephone participants may register in advance to join the call.

How can investors listen to the Neuronetics (STIM) March 17, 2026 webcast?

Investors can listen via the company's live webcast in listen-only mode at the provided webcast URL. According to Neuronetics, telephone participation is also available with prior registration and joining 10 minutes early is recommended for connectivity.

Will Neuronetics (STIM) take live questions during the March 17, 2026 call?

The webcast will be provided in listen-only mode for the March 17, 2026 call and is not set up for live audience Q&A. According to Neuronetics, telephone registration is available but the event is intended primarily to present results and commentary.

Is pre-registration required to join the Neuronetics (STIM) telephone conference on March 17, 2026?

Pre-registration for telephone participation is not required but is recommended ahead of the March 17, 2026 call. According to Neuronetics, registrants should consider joining about 10 minutes early to ensure they are connected before the 8:30 a.m. ET start.